Zevra Therapeutics Inc (ZVRA)
9.13
+0.16
(+1.78%)
USD |
NASDAQ |
Nov 21, 16:00
9.145
+0.02
(+0.16%)
Pre-Market: 20:00
Zevra Therapeutics Enterprise Value: 456.85M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 456.85M |
| November 20, 2024 | 448.31M |
| November 19, 2024 | 448.31M |
| November 18, 2024 | 428.56M |
| November 15, 2024 | 429.63M |
| November 14, 2024 | 451.51M |
| November 13, 2024 | 431.76M |
| November 12, 2024 | 426.96M |
| November 11, 2024 | 447.78M |
| November 08, 2024 | 449.91M |
| November 07, 2024 | 438.46M |
| November 06, 2024 | 438.46M |
| November 05, 2024 | 427.82M |
| November 04, 2024 | 424.62M |
| November 01, 2024 | 416.64M |
| October 31, 2024 | 403.33M |
| October 30, 2024 | 418.24M |
| October 29, 2024 | 409.19M |
| October 28, 2024 | 398.01M |
| October 25, 2024 | 382.04M |
| October 24, 2024 | 390.02M |
| October 23, 2024 | 395.88M |
| October 22, 2024 | 413.44M |
| October 21, 2024 | 424.09M |
| October 18, 2024 | 421.43M |
| Date | Value |
|---|---|
| October 17, 2024 | 423.56M |
| October 16, 2024 | 419.83M |
| October 15, 2024 | 415.57M |
| October 14, 2024 | 399.61M |
| October 11, 2024 | 403.86M |
| October 10, 2024 | 391.09M |
| October 09, 2024 | 420.36M |
| October 08, 2024 | 415.04M |
| October 07, 2024 | 384.17M |
| October 04, 2024 | 352.77M |
| October 03, 2024 | 351.70M |
| October 02, 2024 | 348.51M |
| October 01, 2024 | 334.14M |
| September 30, 2024 | 338.93M |
| September 27, 2024 | 373.19M |
| September 26, 2024 | 393.71M |
| September 25, 2024 | 406.07M |
| September 24, 2024 | 444.22M |
| September 23, 2024 | 407.91M |
| September 20, 2024 | 433.17M |
| September 19, 2024 | 431.06M |
| September 18, 2024 | 421.07M |
| September 17, 2024 | 405.28M |
| September 16, 2024 | 418.44M |
| September 13, 2024 | 422.12M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
36.80M
Minimum
May 11 2022
456.85M
Maximum
Nov 21 2024
157.90M
Average
125.09M
Median
Aug 26 2020
Enterprise Value Benchmarks
| Ionis Pharmaceuticals Inc | 4.154B |
| Vanda Pharmaceuticals Inc | -88.22M |
| BioCardia Inc | 4.858M |
| Xeris Biopharma Holdings Inc | 615.09M |
| Instil Bio Inc | 123.40M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -33.22M |
| Revenue (Quarterly) | 3.695M |
| Total Expenses (Quarterly) | 31.00M |
| EPS Diluted (Quarterly) | -0.69 |
| Gross Profit Margin (Quarterly) | 37.67% |
| Profit Margin (Quarterly) | -899.2% |
| Earnings Yield | -23.11% |
| Normalized Earnings Yield | -22.99 |